Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45  years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial

CONCLUSIONS: This study demonstrated that the novel 4- and 9-valent HPV vaccination was highly immunogenic and generally well tolerated, both of which were non-inferior to Gardasil 4 in immunogenicity and safety.PMID:36283897 | DOI:10.1016/j.vaccine.2022.10.022

Source: Vaccine - October 25, 2022 Category: Allergy & Immunology Authors: Yajun Shu Yebin Yu Ying Ji Li Zhang Yuan Li Haiyang Qin Zhuhang Huang Zhiqiang Ou Meilian Huang Qiong Shen Zehong Li Meng Hu Chunyun Li Gaoxia Zhang Jikai Zhang Source Type: research